Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Gains from Investment Securities: 2018-2024

Historic Gains from Investment Securities for Allogene Therapeutics (ALLO) over the last 7 years, with Dec 2024 value amounting to -$4.3 million.

  • Allogene Therapeutics' Gains from Investment Securities rose 94.75% to -$315,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $500,000, marking a year-over-year decrease of 85.09%. This contributed to the annual value of -$4.3 million for FY2024, which is 161.13% down from last year.
  • Per Allogene Therapeutics' latest filing, its Gains from Investment Securities stood at -$4.3 million for FY2024, which was down 161.13% from $7.0 million recorded in FY2023.
  • In the past 5 years, Allogene Therapeutics' Gains from Investment Securities ranged from a high of $31.4 million in FY2022 and a low of -$4.3 million during FY2024.
  • In the last 3 years, Allogene Therapeutics' Gains from Investment Securities had a median value of $7.0 million in 2023 and averaged $11.4 million.
  • In the last 5 years, Allogene Therapeutics' Gains from Investment Securities soared by 59,155.88% in 2021 and then crashed by 161.13% in 2024.
  • Allogene Therapeutics' Gains from Investment Securities (Yearly) stood at -$34,000 in 2020, then soared by 59,155.88% to $20.1 million in 2021, then soared by 56.19% to $31.4 million in 2022, then crashed by 77.68% to $7.0 million in 2023, then slumped by 161.13% to -$4.3 million in 2024.